A new study highlights how a clinically approved lung cancer drug could potentially be ‘repurposed’ to design new treatments for future cancer therapies. The research focuses on a protein called TRIB2, which is linked to promoting survival and drug resistance in solid tumors and blood cancers and is therefore of particular interest as a therapeutic target.